Influence Instillation Plasma Rich in Growth Factors in Endometrial Cavity Endometrial Development in Assisted Reproduction.

Phase 3TerminatedNCT02996760

IVI Bilbao22 enrolled

Overview

Women in assisted reproduction treatment they receive own or donated embryos and presenting an endometrial development less than 5 mm despite having received treatment with estrogen therapy knowing the clinical value of using the PRGF-Endoret therapy and endometrial level applications to improve endometrial thickness endometrial preparations for embryo transfer.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Endometrial Development

Interventions

Growth Factor, Platelet-DerivedDRUG

0,5 mL, vaginal use , 3 dose number

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 49 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Women receiving cycle of oocytes outside or embryos (own / others), in the treatment of substituted cycle type. * Less than 5mm despite 10 days with standard doses of estrogen therapy (6mg / 24h) Endometrio Exclusion Criteria: * History of pelvic inflammatory disease * Risk of infection

Locations (1)

IVI Bilbao

Leioa, Vizcaya, Spain

Outcomes

Primary Outcomes

To evaluate the growth of endometrial thickness

The endometrial thickness will be measured by vaginal ultrasound. Endometrium less than 5 mm will be treated

Time frame: During ovarian stimulation protocol 8-12 days

Secondary Outcomes

Analyze the impact of using platelet plasma on rates of implantation and pregnancy.

The biochemical determination of the hormone ßhcg will be performed 12 days after embryo transfer

Time frame: During ovarian stimulation protocol 8-12 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.